Glucotrack Buys Out Warrant-Holder Protections With 406,198 New Warrants at $7.50
GCTK is trading near its 52-week low of $0.682 (0.4% above the low).
Summary
Glucotrack got its July warrant holders to waive a 90-day equity-issuance standstill and a variable-rate price ratchet, paying them with 406,198 new warrants at a $7.50 strike. The move clears the way for more financings but adds another layer of potential dilution.
Key Events · Financing and Capital Events · GCTK
-
Warrant Holders Waive Key Protections
Holders of the July 14, 2026 warrants signed a waiver on October 13, 2026 terminating the Section 5.10(a) 90-day equity issuance standstill and the Section 3(e) variable-rate exercise price adjustment right.
-
406,198 New Warrants at $7.50
Consideration is 406,198 new warrants struck at $7.50 per share — about 11x today's $0.68 price — with a five-year term, a 9.99% ownership cap, and a floor price at 20% of the closing price on issuance.
-
Stockholder Approval Required First
The new warrants are not exercisable until Glucotrack obtains stockholder approval under Nasdaq Listing Rule 5635; the company must use commercially reasonable efforts to get it.
-
Clears Path to More Financing
Removing the standstill and ratchet lets Glucotrack pursue variable-rate financings — the type it used in the September convertible notes and the pending $50M equity line — without triggering a price reset for these holders.
Analysis · GCTK · Industrial Applications And Services
Glucotrack paid the holders of its July 2026 warrants to surrender two protections: a 90-day ban on new equity issuance and a ratchet that would have cut their exercise price if the company did a variable-rate deal. Why it matters: Glucotrack is a going-concern-risk microcap that has been funding itself through exactly those kinds of transactions — the September convertible notes and the pending $50M equity line — so the standstill was a live obstacle to raising cash. The price of that permission is 406,198 new warrants struck at $7.50, roughly eleven times today's $0.68 share price. They are far out of the money and cannot be exercised until stockholders approve the share issuance under Nasdaq rules. The real cost is the overhang and the signal: the company is clearing the contractual path to more dilution while its stock sits near a 52-week low, and the new warrants stack on top of the 43.2M shares already registered for resale in the October 14 S-1/A.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 29.2% of the 1549 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GCTK was trading at $0.68 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $697K. The 52-week trading range was $0.68 to $112.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.